423 reports of this reaction
1.4% of all CLOTRIMAZOLE reports
#17 most reported adverse reaction
THERAPEUTIC PRODUCT EFFECT INCOMPLETE is the #17 most commonly reported adverse reaction for CLOTRIMAZOLE, manufactured by Bayer HealthCare LLC.. There are 423 FDA adverse event reports linking CLOTRIMAZOLE to THERAPEUTIC PRODUCT EFFECT INCOMPLETE. This represents approximately 1.4% of all 29,744 adverse event reports for this drug.
Patients taking CLOTRIMAZOLE who experience therapeutic product effect incomplete should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THERAPEUTIC PRODUCT EFFECT INCOMPLETE is a less commonly reported adverse event for CLOTRIMAZOLE, but still significant enough to appear in the safety profile.
In addition to therapeutic product effect incomplete, the following adverse reactions have been reported for CLOTRIMAZOLE:
The following drugs have also been linked to therapeutic product effect incomplete in FDA adverse event reports:
THERAPEUTIC PRODUCT EFFECT INCOMPLETE has been reported as an adverse event in 423 FDA reports for CLOTRIMAZOLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
THERAPEUTIC PRODUCT EFFECT INCOMPLETE accounts for approximately 1.4% of all adverse event reports for CLOTRIMAZOLE, making it a notable side effect.
If you experience therapeutic product effect incomplete while taking CLOTRIMAZOLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.